Professor Rönnberg brings extensive expertise in veterinary oncology, pharmacology, and translational drug development, further strengthening Immuvera’s scientific and clinical foundation as the company advances Nebumet, its inhaled immunotherapy platform for the prevention and treatment of lung metastases in dogs.

He is currently Professor in Veterinary Pharmacology at the Swedish University of Agricultural Sciences (SLU) and previously served as Professor in Internal Medicine – Small Animals at SLU. In addition to his academic career, Professor Rönnberg has held senior industry roles, including serving as Chief Medical Officer at Oasmia Pharmaceutical AB.

Professor Rönnberg was the first nationally recognised specialist in small animal oncology in Sweden and is a Diplomate in Oncology of the European College of Veterinary Internal Medicine – Companion Animals (DECVIM-CA Oncology). He is also among the co-founders of the oncology college within ECVIM-CA. His background combines clinical oncology, academic leadership, pharmacology, and therapeutic development, making his perspective highly relevant to Immuvera’s development strategy.

His appointment reflects Immuvera’s commitment to building a world-class advisory network around the development of innovative therapies.

Lars Moe, CMO of Immuvera Therapeutics, said:
“Professor Rönnberg brings highly valuable expertise in veterinary oncology, pharmacology, and translational development. His broad experience from both academia and industry will be an important asset to Immuvera as we continue advancing Nebumet.”

As Immuvera moves Nebumet toward pivotal development and regulatory progression, the company remains focused on working with leading international experts to support the development of new therapies for companioin animals.